The drugmaker and medical technology company sold its remaining shares in two previous partners.

Johnson & Johnson (JNJ) is rated a Hold: defensive quality, DCF valuation, easing litigation, and dividend outlook—see key ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a ...

"The company knew that its talc-based products were routinely contaminated with asbestos and other carcinogens, but chose to deny and cover up that knowledge for decades,” stated Leigh O’Dell of the ...

Royalty Pharma has inked a $500 million research-and-development co-funding agreement with Johnson & Johnson to support development of a proposed drug for autoimmune diseases.

Johnson & Johnson has crushed the market over the past year. The healthcare giant faces some challenges that could harm its results. However, Johnson & Johnson's business looks strong enough to ...

Johnson & Johnson on Wednesday announced plans to invest more than $1 billion in a next-generation manufacturing facility that will produce advanced cell therapy technologies. The facility will be ...

From Philly and the Pa. suburbs to South Jersey and Delaware, what would you like WHYY News to cover? Let us know! Pharmaceutical manufacturer Johnson & Johnson is expanding its operations in ...

Bayer BAYGn.DE sued Johnson & Johnson JNJ.N on Monday, accusing the drugmaker of falsely advertising a rival multibillion-dollar drug to treat prostate cancer. In a complaint filed in Manhattan ...